BR112017022255A2 - anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica - Google Patents

anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica

Info

Publication number
BR112017022255A2
BR112017022255A2 BR112017022255A BR112017022255A BR112017022255A2 BR 112017022255 A2 BR112017022255 A2 BR 112017022255A2 BR 112017022255 A BR112017022255 A BR 112017022255A BR 112017022255 A BR112017022255 A BR 112017022255A BR 112017022255 A2 BR112017022255 A2 BR 112017022255A2
Authority
BR
Brazil
Prior art keywords
antibody
isolated
vector
producing
nucleic acid
Prior art date
Application number
BR112017022255A
Other languages
English (en)
Inventor
Dufour Florent
Radvanyi François
Haegel Hélène
Bernard-Pierrot Isabelle
Menguy Thierry
Duong Vanessa
Original Assignee
Centre Nat Rech Scient
Elsalys Biotech
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Elsalys Biotech, Inst Curie filed Critical Centre Nat Rech Scient
Publication of BR112017022255A2 publication Critical patent/BR112017022255A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

a presente invenção refere-se a anticorpos, em particular, anticorpos humanos ou humanizados, que se ligam ao domínio extracelular de receptor tyro3 humano, em particular, ao domínio do tipo imunoglobulina ig-1, e reduzem ou inibem a ligação de gas6 humano ao dito receptor. a invenção também se refere aos usos desses anticorpos no diagnóstico, na prevenção ou no tratamento de doenças hiperproliferativas ou infecciosas.
BR112017022255A 2015-04-17 2016-04-15 anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica BR112017022255A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305581 2015-04-17
PCT/EP2016/058457 WO2016166348A1 (en) 2015-04-17 2016-04-15 Anti-tyro3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112017022255A2 true BR112017022255A2 (pt) 2018-08-28

Family

ID=52998002

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022255A BR112017022255A2 (pt) 2015-04-17 2016-04-15 anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica

Country Status (8)

Country Link
US (1) US20180105596A1 (pt)
EP (1) EP3283523A1 (pt)
JP (1) JP2018512892A (pt)
KR (1) KR20170138494A (pt)
CN (1) CN108064245A (pt)
BR (1) BR112017022255A2 (pt)
CA (1) CA2982657A1 (pt)
WO (1) WO2016166348A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2020047462A2 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US11738052B2 (en) 2019-06-21 2023-08-29 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
US20230174666A1 (en) 2020-04-29 2023-06-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3184756A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN1238367C (zh) * 1998-10-26 2006-01-25 路德维格癌症研究院 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
US20070098715A1 (en) * 2005-03-25 2007-05-03 Seth Ettenberg Antibodies against the tenascin major antigens
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
SI3279215T1 (sl) * 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
AR082017A1 (es) * 2010-06-18 2012-11-07 Genentech Inc Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso

Also Published As

Publication number Publication date
WO2016166348A1 (en) 2016-10-20
US20180105596A1 (en) 2018-04-19
KR20170138494A (ko) 2017-12-15
CN108064245A (zh) 2018-05-22
CA2982657A1 (en) 2016-10-20
JP2018512892A (ja) 2018-05-24
EP3283523A1 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
PH12017500890A1 (en) Antibody drug conjugates
BR112017025693A2 (pt) anticorpos anti-cd40 e seus usos
MX2021003436A (es) Anticuerpos humanos para pd-1.
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
MX2016012830A (es) Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
BR112015017619A2 (pt) formulação líquida, uso de uma formulação, e, kit
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
EP3492101A3 (en) Agents for influenza neutralization
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos
BR112013003257A2 (pt) anticorpos egfr humanizados.
EA201400447A1 (ru) АНТИТЕЛА К CD1d
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado
IN2014DN09717A (pt)
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
BR112016022508A2 (pt) anticorpos contra hpa-1a
BR112018070452A2 (pt) um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]